Clinical-stage biotechnology company
Appears in 1 story
Acquired by AbbVie; deal expected to close Q3 2026
Patients with moderate to severe atopic dermatitis on the mid-dose of zumilokibart hit 65.9% skin clearance at 16 weeks, versus 23.4% on placebo. AbbVie presented the Phase 2 results as a late-breaker at the European Academy of Dermatology and Venereology congress in Vienna on Sept. 30.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
